Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study
Laurens A. Kleef, Milan J. Sonneveld, Maryam Kavousi, M. Arfan Ikram, Robert A. Man, Robert J. Knegt – 25 June 2022
Moving computed tomography–based quantification of muscle mass to the mainstream: Validation of a web‐based platform to calculate skeletal muscle index in cirrhosis
Penelope Hey, Melissa Chew, Darren Wong, Paul Gow, Adam Testro, Numan Kutaiba, Marie Sinclair – 25 June 2022
Neonates with acute liver failure have higher overall mortality but similar posttransplant outcomes as older infants
Swati Antala, Bridget Whitehead, Justin Godown, Matt Hall, Anna Banc‐Husu, Estella M. Alonso, Sarah A. Taylor – 24 June 2022 – Neonatal acute liver failure (ALF) carries a high mortality rate; however, little data exist on its peritransplant hospital course. This project aimed to identify factors associated with outcomes in neonates with ALF using large multicenter databases.
Letter to the editor: Using intratumoral steatosis to predict the efficacy of combination therapy in nonviral hepatocellular carcinoma
Shi‐Tao Jiang, Yi‐Yao Xu, Xin Lu – 24 June 2022
CAQ Corner: Immune‐mediated complications
Mary Thomson, John R. Lake – 23 June 2022
Graft aberrant hepatic arteries in deceased donor liver transplantation: The “one liver, one artery” approach
Riccardo Pravisani, Ailton Sepulveda, Lorenzo Cocchi, Estrella Mello, Francois Cauchy, Safi Dokmak, Olivier Farges, Francois Durand, Emmanuel Weiss, Federica Dondero, Mickaël Lesurtel – 23 June 2022 – In liver transplantation (LT), graft aberrant hepatic arteries (aHAs) frequently require complex arterial reconstructions, potentially increasing the risk of post‐operative complications. However, intrahepatic hilar arterial shunts are physiologically present and may allow selective aHA ligation.
Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: A 7‐year national inpatient sample study
Bing Chen, Yichen Wang, Marcia Lange, Tatyana Kushner – 23 June 2022 – Prior international studies have shown mixed results regarding the association of hepatitis B and hepatitis C with adverse pregnancy outcomes. We performed an updated evaluation of the prevalence of associated adverse pregnancy outcomes and evaluated trends over time of diagnosis of chronic hepatitis B (HBV) and chronic hepatitis C (HCV) in pregnant women in a national database. All pregnant women with HBV and HCV were identified from the National Inpatient Sample database 2012 to 2018.
CAQ Corner: Immune‐mediated complications
Mary Thomson, John R. Lake – 23 June 2022
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis
Archana Vijayakumar, Ayse Okesli‐Armlovich, Ting Wang, Isabel Olson, Minji Seung, Saritha Kusam, David Hollenback, Sangeetha Mahadevan, Bruno Marchand, Maria Toteva, David G. Breckenridge, James L. Trevaskis, Jamie Bates – 22 June 2022 – Dysregulated hepatocyte lipid metabolism is a hallmark of hepatic lipotoxicity and contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH).
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates
Eleanor Barnes, Graham S. Cooke, Georg M. Lauer, Raymond T. Chung – 22 June 2022 – Hepatitis C virus (HCV) remains a major global health concern. Directly acting antiviral (DAA) drugs have transformed the treatment of HCV. However, it has become clear that, without an effective HCV vaccine, it will not be possible to meet the World Health Organization targets of HCV viral elimination. Promising new vaccine technologies that generate high magnitude antiviral T and B cell immune responses and significant new funding have recently become available, stimulating the HCV vaccine pipeline.